The rapid release of trial results for sodium-glucose cotransporter 2 inhibitors (SGLT2i) and emerging indications demonstrate an exciting new treatment option for patients at high cardiovascular risk. Once considered to fall within the purview of endocrinologists and primary care providers, SGLT2i’s are now therapies that cardiac care providers must consider for their ASCVD and HF patients.

Learn more about the FDA indications and novel mechanisms of canagliflozin, dapagliflozin, and empagliflozin, guideline-directed treatments of ASCVD, hypertension, and HF treatment options, and explore the benefits of these therapies for patients with impaired renal function. Throughout this course you’ll gain insights on the latest science and practical applications you need to deliver cutting-edge therapy to your patients.

	Certified Patient Cases Apply your knowledge of SGLT2i’s and their role in CV risk reduction for high risk patients through these certified patient cases. Case 1: Wading into the Unknown: Starting SGLT2 Inhibitors Case 2: Now What? Considerations after Initiating SGLT2 Inhibitor Therapy
	Self-Paced Learning SGLT2i’s Beyond Diabetes: From Trials to Treatment Strategies eLearning curriculum will decipher the wave of new trial evidence and review the novel mechanisms and clinical indications for SGLT2i’s. Navigating the Changing Landscape of SGLT2 Inhibitor Trials SGLT2i Mechanism of Action and Practical Approaches to Therapy
	Webinar Join chair James L. Januzzi Jr, MD, FACC, and expert faculty Alison Bailey, MD, FACC, Michelle M. Kittleson, MD, FACC, Melissa Magwire, CDE, MSN, RN, and Muthiah Vaduganathan, MD for a virtual session to gain insights on the latest science and practical applications you need to deliver cutting-edge therapy to your patients. Meeting On Demand

Click here to see additional Spotlight Topics in the Clinical Spotlight Series